RESUMO
In two prospective, randomized multicenter double-blind studies with a dosage of either 250 mg given four times a day (study A) or 500 mg given two times a day (study B), the comparative efficacy and safety of cephalexin hydrochloride (LY061188; Keftab) and cephalexin monohydrate (Keflex) for treatment of skin and soft tissue infections were determined. In study A, 97 patients received cephalexin hydrochloride and 101 patients received cephalexin monohydrate. In study B, 75 patients received cephalexin hydrochloride and 70 patients received cephalexin monohydrate. Diagnoses included abscesses, cellulitis, wound infections, and infected dermatitis, and were comparable in the different treatment groups. Pathogens were isolated from 82% of patients enrolled; the majority of isolates were of Staphylococcus aureus, Streptococcus pyogenes, other staphylococcal species, and a few gram-negative bacteria. In study A, 68 of 71 (95.7%) evaluable patients who received cephalexin hydrochloride responded satisfactorily; 73 of 81 (90%) patients who received cephalexin monohydrate also responded satisfactorily. In study B, 56 of 58 (96.5%) evaluable patients who received cephalexin hydrochloride responded satisfactorily; 47 of 50 (94%) patients who received cephalexin monohydrate also responded satisfactorily. An adverse clinical event leading to discontinuation of the treatment drug developed in 17 of 343 (4.95%) patients in both studies. No differences were noted between the two drugs. Skin eruptions, pruritus, and mild gastrointestinal symptoms were the common adverse effects. These data suggest that cephalexin hydrochloride, a new formulation of cephalexin, is a safe and effective antimicrobial agent for treatment of a variety of skin and subcutaneous infections in a dosage of either 250 mg four times a day or 500 mg twice a day.
Assuntos
Infecções Bacterianas/tratamento farmacológico , Cefalexina/uso terapêutico , Dermatopatias Infecciosas/tratamento farmacológico , Adulto , Infecções Bacterianas/microbiologia , Cefalexina/efeitos adversos , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Humanos , Masculino , Distribuição Aleatória , Dermatopatias Infecciosas/microbiologiaAssuntos
Cefaclor/uso terapêutico , Cefalexina/análogos & derivados , Dermatopatias Infecciosas/tratamento farmacológico , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estreptocócicas/tratamento farmacológico , Adolescente , Adulto , Idoso , Cefaclor/efeitos adversos , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Staphylococcus aureusAssuntos
Antibacterianos/farmacologia , Dermatopatias Infecciosas/fisiopatologia , Infecções Estafilocócicas/fisiopatologia , Staphylococcus aureus/efeitos dos fármacos , Infecções Estreptocócicas/fisiopatologia , Streptococcus/efeitos dos fármacos , Ampicilina/farmacologia , Humanos , Impetigo/fisiopatologia , Testes de Sensibilidade Microbiana , Penicilina G/farmacologia , Resistência às Penicilinas , Pioderma/fisiopatologia , Dermatopatias Infecciosas/microbiologia , Staphylococcus aureus/fisiologia , Streptococcus/fisiologiaRESUMO
Psoriasis of fingernails and toenails presents a challenge that has not been met by the available therapeutic modalities. Three cases of treatment with x-ray therapy of varying intensities are presented herein. Cure was acheived in all three cases with no x-ray sequelae.